Sean Mackay, IsoPlexis
January 8, 2021 10:44 AM ESTUpdated July 26, 02:25 PM
Financing

Iso­Plex­is scores big backer for per­son­al­ized pro­tein 'bar­codes' as Per­cep­tive jumps on board new fund­ing round

Max Gelman

Senior Editor

A lit­tle less than two years af­ter bag­ging an ex­tend­ed $50 mil­lion Se­ries C, Iso­Plex­is and its “pro­teom­ic bar­codes” for per­son­al­ized can­cer care are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times